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The increased prevalence of drug-resistant human pathogenic
fungal diseases poses a major threat to global human health. Thus,
new drugs are urgently required to combat these infections. Here, we
demonstrate that acetohydroxyacid synthase (AHAS), the first enzyme
in the branched-chain amino acid biosynthesis pathway, is a promising
new target for antifungal drug discovery. First, we show that several
AHAS inhibitors developed as commercial herbicides are powerful
accumulative inhibitors of Candida albicans AHAS (Ki values as low as
800 pM) and have determined high-resolution crystal structures of this
enzyme in complex with several of these herbicides. In addition, we
have demonstrated that chlorimuron ethyl (CE), a member of the
sulfonylurea herbicide family, has potent antifungal activity against
five different Candida species and Cryptococcus neoformans (with min-
imum inhibitory concentration, 50% values as low as 7 nM). Further-
more, in these assays, we have shown CE and itraconazole (a
P450 inhibitor) can act synergistically to further improve potency. Fi-
nally, we show in Candida albicans-infected mice that CE is highly
effective in clearing pathogenic fungal burden in the lungs, liver, and
spleen, thus reducing overall mortality rates. Therefore, in view of their
low toxicity to human cells, AHAS inhibitors represent a new class of
antifungal drug candidates.
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The number of diagnosed pathogenic fungal infections con-tinues to rise significantly each year, with an estimated 1 bil-
lion people worldwide now at risk (1) and ∼2 million people per
annum succumbing to these infections (2), a number that exceeds
the annual death toll for tuberculosis or malaria (3). Despite this,
major advances in the search for novel antifungal treatments have
been a rarity (4). Individuals commonly affected by fungal infections
(e.g., candidiasis, cryptococcosis, aspergillosis, or Pneumocystis pneu-
monia) are transplant recipients, the immunocompromised suffering
HIV, or patients receiving immunosuppressant therapy. However,
existing antifungal therapeutics are limited to just a few classes of
drugs (e.g., polyenes, azoles, echinocandins, and fluorinated pyrim-
idine analogs), and these are costly to produce. Furthermore,
treatment using these medications requires high doses to be taken
over a prolonged time, which can result in serious side effects and
lack of compliance (5, 6). In addition to these factors, several clin-
ically relevant pathogenic fungi, including Aspergillus fumigatus,
Candida glabrata, Candida krusei, and Cryptococcus spp., are in-
trinsically resistant to some first-line antifungals (4, 5, 7). More-
over, acquired resistance to all these classes of antifungal drugs
has been extensively reported (8–11), and the prevalence of
multidrug-resistant strains of pathogenic fungi is continuing to
rise (4, 12). Thus, it is clear that new drugs are urgently needed
to combat this major threat to human health.
A potential target for the development of new antifungal drugs
is acetohydroxyacid synthase (AHAS; EC 2.2.1.6), the first enzyme in
the branched-chain amino acid (BCAA) biosynthesis pathway.
BCAAs are synthesized by a common pathway in plants and micro-
organisms; however, this pathway is absent in animals, making it an
especially attractive drug target (13). It has previously been shown that
AHAS activity is crucial for survival of Candida albicans and Crypto-
coccus neoformans in vitro, and BCAA auxotrophic strains of these
two fungal pathogens are avirulent in vivo (14, 15). These findings
suggest AHAS inhibitors could be useful as antifungal agents.
It has been 30 y since the first AHAS inhibitors were introduced as
commercial herbicides, with five families of compounds [i.e., sulfo-
nylureas (SUs), imidazolinones (IMIs), pyrimidinyl-benzoates (PBs),
triazolopyrimidines (TPs), and sulfonylamino-carbonyl-triazolinones
(SCTs)] still in use today (16), which is a testament to their robustness
as biocidal agents. Further enhancing their credentials as drug can-
didates, these compounds display low toxicity in mammals (LD50 in
rat >5 g/kg), which is expected since animals do not possess the
BCAA pathway (13, 17). Studies on AHAS inhibitors as antifungals
have been sporadic and inconclusive. Chlorimuron ethyl (CE) (Fig.
1A), an SU herbicide, has previously been shown to inhibit the growth
of C. albicans in culture with a minimum inhibitory concentration,
50% (MIC50) of 2 μM (18), and several noncommercial TPs have
activity against C. albicans, C. neoformans, and A. fumigatus with
MIC50 values in the range of 1–4 μg/mL (19). However, beyond these
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reports, a comprehensive study into the suitability of the AHAS-
inhibiting herbicides as antifungal agents has yet to be undertaken.
Results
CaAHAS and CnAHAS Inhibition by Commercial Herbicides. Repre-
sentatives of the five families of herbicides that target AHAS (SI
Appendix, Fig. S1) were tested as inhibitors of C. albicans (Ca)
AHAS and C. neoformans (Cn) AHAS. Members of the SU and
TP families are the most potent inhibitors (Table 1), with CE
having a Ki of 24.26 nM for CaAHAS and 119.7 nM for CnAHAS
(Fig. 1B), metosulam (MT) a Ki of 800 pM for CaAHAS, and
cloransulam methyl a Ki of 35.3 nM for CnAHAS. Members of the
SCT, PB, and IMI families inhibit CaAHAS, but with Ki values only
in the micromolar range, while the SCTs and PBs inhibit CnAHAS,
with Ki values in the millimolar range (Table 1). CnAHAS is partially
resistant to SU herbicides, including bensulfuron methyl (BSM),
ethoxysulfuron (ES), and sulfometuron methyl (SM). This lower in-
hibitory activity appears to be due to the P188A and A191L substi-
tutions in the CnAHAS herbicide binding pocket compared with
CaAHAS (discussed below) (SI Appendix, Fig. S2A). Two noncom-
mercial SUs derived from the chemical structure of CE, iodomuron
ethyl (IE) and iodomuron methyl (IM) (18) (SI Appendix, Fig. S1),
were also tested as inhibitors of the fungal enzymes. Compared with
CE, these compounds show a two- to fourfold reduction in the Ki
values against CaAHAS; however, this improvement in binding af-
finity is not extended to CnAHAS (Table 1).
Recently, we demonstrated AHAS inhibition by commercial
herbicides fits a model of time-dependent accumulative inhibition
from which first-order rate constants of enzyme inactivation (kiapp)
and enzyme recovery (k3) can be determined (20). Here, we found
that the five families of herbicides show different levels of reversible
accumulative inhibition for CaAHAS and CnAHAS (Table 1 and
SI Appendix, Fig. S3). The kiapp and k3 values were determined by
curve fitting to Eq. 3 (20) and show that three families of herbicides
(i.e., SUs, TPs, and SCTs) are highly effective in promoting the in-
activation of CaAHAS (kiapp values from 0.33 to 21.26 min
−1). De-
spite the high level of conservation observed in the herbicide-binding
site of CnAHAS and CaAHAS (SI Appendix, Fig. S2A), the former
enzyme is less prone to undergo inactivation by commercial herbi-
cides with kiapp values in the range of 0.13–3.99 min
−1. k3 values for
CaAHAS in the presence of IE, and for CnAHAS in the presence of
pyroxsulam (PYS), flumetsulam (FT), or propoxycarbazone (PC) are
so low that the inactivation evoked by these herbicides is virtually ir-
reversible (Table 1). This implies that, when kiapp >> k3, the enzyme’s
ability to recover from herbicide-induced inactivation determines the
potency of accumulative inhibition (kiapp/k3).
CaAHAS Overall Structure. Crystal structures of the catalytic sub-
unit of uninhibited CaAHAS and CaAHAS in complex with
eight different herbicidal inhibitors were determined at resolu-
tions ranging from 1.81 to 2.97 Å (SI Appendix, Table S1).
CaAHAS is homotetrameric (Fig. 2A) consistent with Arabi-
dopsis thaliana (At) AHAS but different from Saccharomyces
cerevisiae (Sc) AHAS, which is homodimeric (SI Appendix, Fig.
S4A). The overall fold for the polypeptide of uninhibited
CaAHAS closely resembles that of uninhibited ScAHAS (SI
Appendix, Fig. S4B) but differs significantly in the capping region
[“mobile loop” (Q576–Y591) and “C-terminal arm” (P646–Y683)]
(Fig. 2B). In uninhibited ScAHAS the majority of residues in these
two regions are not observed in the electron density maps or adopt
a different fold (e.g., an antiparallel β-sheet from V583 to H597 is
observed in ScAHAS that changes to a helix when herbicide
binds) (21) (SI Appendix, Fig. S4B). In this respect, CaAHAS
more closely resembles that of uninhibited AtAHAS (rmsd =
0.699 Å when 428 Cα of a single polypeptide are superposed) that
has a folded capping region and preformed binding pocket for the
herbicide (22) (SI Appendix, Fig. S4B).
In the uninhibited CaAHAS structure the entire polypeptide is
well-resolved, except for the regions between I192–Q198 and
N267–A276. Importantly, I192–Q198 is in the vicinity of the
active site, forming part of the substrate access channel and herbicide-
binding site (SI Appendix, Fig. S5A). Upon herbicide binding, these
residues are locked in position by direct contacts to the herbicides (SI
Appendix, Fig. S5B). The N267–A276 region is remote from the ac-
tive site and herbicide-binding site and not likely to influence the
binding of substrates, cofactors, or inhibitors (Fig. 2B).
The electron densities for FAD, thiamine diphosphate (ThDP),
and magnesium ion (Mg2+) and for the herbicides are all un-
equivocal, noting that in all of the enzyme-inhibitor complexes
the chemical structure of ThDP is chemically modified (Fig. 2C).
When the SCT, PC, binds ThDP is modified to thiamine thia-
zolone diphosphate (ThThDP), and when the SUs, BSM, IE,
and IM, or the TP, PS, bind the cofactor is altered to thiamine
aminoethenethiol diphosphate (ThAthDP). However, the elec-
tron densities in the CaAHAS–SM and the CaAHAS–MT
complexes suggest both ThThDP and ThAthDP are present.
In contrast, the crystallographic data of the CaAHAS–CE complex
suggests that ThAthDP along with an intermediate product of deg-
radation of ThDP, thiamine formamidoethenethiol diphosphate
(ThFAthDP), are present. The assignment of these chemical modifi-
cations was confirmed by MS of the cofactor isolated from a solution
of enzyme incubated with inhibitor (SI Appendix, Fig. S6). Herbicide
(e.g., PB, SCT, and TP families)-induced modifications to ThDP have
also been observed for AtAHAS (23, 24), and these are the result of
oxidative reactions that promote the formation of peracetate in the
active site (24) and the subsequent alteration of ThDP (Fig. 3). Im-
portantly, ThThDP has been attributed to have antimetabolic activity
(ThDP antagonist) (25) and reactive oxygen species, such as per-
acetate, inhibit C. albicans growth via NADH depletion (26). These
factors, in addition to ThDP’s being replenished at a metabolic cost to
cells, could be major contributors to biocidal activity.
CaAHAS Structures in Complex with Herbicide. To understand the
molecular basis of herbicide inhibition of CaAHAS, we cocrys-
tallized this enzyme in complex with five SUs, CE, BSM, SM, IE,
and IM; two TPs, MT and PS; and the SCT, PC (SI Appendix,
Table S1). The overall fold of these structures is similar to that of
the uninhibited enzyme, with rmsd values between 0.145 and
0.271 Å when all Cα atoms are superposed, but in these struc-
tures the I192–Q198 region, which is involved in herbicide
binding (SI Appendix, Fig. S5), is now fully resolved.
Herbicide Binding Mode to CaAHAS.All eight herbicides are located
in a binding pocket (Figs. 2D and 4) that is situated above the
active site and thus operate by preventing the substrate, pyruvate,
access to ThDP (SI Appendix, Fig. S5A). This pocket is formed by
12 residues and FAD (SI Appendix, Fig. S7) and is the putative
binding site of quinones, which inhibit AHAS activity via FAD
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Fig. 1. Inhibition of CaAHAS and CnAHAS by CE. (A) Chemical structure of
CE. (B) Percentage of enzyme activity vs. inhibitor concentration. The solid
line represents the best fit to the data using the equation for weak to me-
dium binding (Eq. 1; CnAHAS) or for tight-binding (Eq. 2; CaAHAS). Error
bars represent the SD of the mean (SEM) (n = 3).
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oxidation (27). Key to the binding of the three families of herbi-
cides are the contacts formed with P188, F187, K247, M350, R376,
M578, and W582 (Fig. 4 and SI Appendix, Fig. S8). Except for
P188, all these residues are highly conserved and located in the
deepest part of the herbicide-binding site (SI Appendix, Fig. S2B).
K247 and R376 contribute with up to five hydrogen bonds when
the SUs or the SCT, PC, bind (Fig. 4 A and C), whereas between
four to six hydrogen bonds are formed with the TPs (Fig. 4B). In
addition, the guanidinium group of R376 forms a π cation in-
teraction with the aromatic ring of the herbicide. The remaining
residues of the herbicide-binding site form a large hydrophobic
surface (SI Appendix, Fig. S7) that accounts for 30–50 noncovalent
interactions. Of these, probably the most important are the π
staking interaction formed between the side chain of W582 and
the heterocyclic ring of the herbicide and the carbon–π interaction
with P188, both of which anchor the herbicide in the binding
pocket. A more detailed analysis of the binding mode of each
family of herbicides is available as SI Appendix.
An overlay of the CE complex with an example of the other
herbicide complexes shows that the three different families
partially overlap their modes of binding to CaAHAS (SI Ap-
pendix, Fig. S9). The aromatic rings, and the sulfonyl and car-
bonyl groups of the SUs and the SCT, PC, are the only
components of these two families that adopt a similar position
and conformation. In contrast, the TPs have a different orien-
tation, with the aromatic ring overlapping with the ester sub-
stituent of the SUs or SCTs and the heterocyclic and linker
moieties inserted deepest in the herbicide-binding site.
Conformational Changes in CaAHAS upon Herbicide Binding. A
comparison of uninhibited CaAHAS and the CaAHAS-inhibitor
complexes shows that, in the uninhibited enzyme, R376 and
W582 protrude toward the herbicide-binding cavity and occupy
the location taken by the heterocyclic ring of all three families of
herbicides (SI Appendix, Fig. S9). This implies that these residues
would block herbicide binding. However, the side chains of
R376 and W582 change their conformation so as to make numer-
ous contacts with the herbicides. The adjustments of W582 are the
most important for herbicide binding because these allow the π
stacking interaction that locks the herbicides into the binding
pocket. Other residues in the herbicide-binding site, including P188,
A191, K247, and D375, undergo less pronounced side-chain and
backbone adjustments to accommodate the herbicides (SI Appendix,
Fig. S9). Compared with AtAHAS (22, 23) the herbicide-binding
site in CaAHAS is much more rigid and ready to receive inhibitors
with only minor conformational changes, a feature of importance
for the rational design of alternative CaAHAS inhibitors.
Effect of P188A and A191L Substitutions in CnAHAS. To understand
why some SU herbicides are potent inhibitors of CaAHAS but
fail to inhibit CnAHAS we performed in silico mutation and
energy minimization of P188A and A191L on the structures of
uninhibited CaAHAS and for the CE and MT complexes. These
models show that in the P188A substitution key nonpolar in-
teractions (including CH–π interactions; see SI Appendix, Fig.
S7) formed between P188 and the aromatic ring of the SUs are
no longer present due to the smaller alanine side chain (SI Ap-
pendix, Fig. S2C). However, the side chain of leucine in the
A191L substitution protrudes toward the binding cavity, re-
ducing its volume; therefore, conformational adjustments are
required to accept the herbicide (SI Appendix, Fig. S2C). Al-
though extra contacts may be formed in the presence of this
substitution, the overall effect of the P188A and A191L substi-
tutions is negative as witnessed by the increase in the Ki value of
CE and resistance in the presence of SM, BSM, and ES. In
contrast, the Ki values of the TPs are less affected by these
Table 1. Inhibition constants and kinetic rate constants of accumulative inhibition of commercial herbicides for
fungal AHASs
Inhibitor
C. albicans C. neoformans
Ki, nM kiapp, min
−1 k3, min
−1 kiapp/k3 Ki, nM kiapp, min
−1 k3, min
−1 kiapp/k3
SU
IE 6.3 ± 0.7 0.33 ± 0.05 3.3 × 10−11 10 × 1010 110.5 ± 10.8 0.17 ± 0.02 0.023 7.4
IM 12.7 ± 1.1 1.10 ± 0.15 0.020 55.0 472.7 ± 25.5 0.17 ± 0.03 0.056 3.0
CE 24.3 ± 2.5 1.00 ± 0.32 0.045 22.2 119.7 ± 4.2 0.73 ± 0.03 0.022 33.0
BSM 29.9 ± 2.7 1.82 ± 0.25 0.064 28.4 NI — — —
ES 69.3 ± 6.9 1.69 ± 0.20 0.082 20.6 NI — — —
CS 570 ± 59 NP NP — 769 ± 89 × 103 NP NP —
SM 630 ± 51 0.67 ± 0.14 0.081 8.3 NI — — —
TP
MT 0.8 ± 0.1 3.39 ± 0.69 0.023 147.4 65.4 ± 4.9 1.14 ± 0.06 0.029 39.3
DS 1.7 ± 0.8 2.31 ± 0.20 0.071 32.5 901.0 ± 72.9 0.13 ± 0.02 0.007 18.6
PS 2.4 ± 0.3 15.26 ± 3.42 0.074 206.2 331.1 ± 20.0 2.18 ± 0.11 0.037 58.9
CSM 4.6 ± 1.2 3.86 ± 0.54 0.052 74.2 35.3 ± 3.7 0.94 ± 0.06 0.018 52.2
FS 10.1 ± 1.7 5.97 ± 0.40 0.068 87.8 590 ± 41.0 0.67 ± 0.03 0.025 26.8
PYS 212 ± 18 2.26 ± 0.10 0.067 33.7 320 ± 29 × 103 3.99 ± 0.60 5.3 × 10−10 7.5 × 109
FT 773 ± 62 3.78 ± 0.27 0.068 55.6 137 ± 9 × 103 2.00 ± 0.59 1.5 × 10−10 1.4 × 1010
SCT
PC 484 ± 37 1.83 ± 0.28 0.080 22.9 9.4 ± 1.6 × 103 0.19 ± 0.04 3.7 × 10−11 5.1 × 109
TCM 28 ± 6 × 103 21.3 ± 4.4 0.109 195.0 1.2 ± 0.2 × 106 NP NP —
PB
BS 2.6 ± 0.3 × 103 NP NP — 5.8 ± 0.6 × 106 NP NP —
PTB 403 ± 37 × 103 NP NP — 765 ± 65 × 103 NP NP —
IMI
IQ 716 ± 61 × 103 NP NP — NI — — —
IT 4.3 ± 0.7 × 106 NP NP — NI — — —
BS, bispyribac; CS, chlorsulfuron; CSM, cloransulam methyl; DS, diclosulam; FS, florasulam; IQ, imazaquin; IT, imazethapyr; NI, no
inhibition detected; NP, no reversible accumulative inhibition present; PS, penoxsulam; PTB, pyrithiobac; TCM, thiencarbazone methyl.
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substitutions (Table 1). In the light of these results, this appears
to be because these herbicides rely less on the interactions
formed with P188 than on the additional contacts that may occur
with the A191L substitution (SI Appendix, Fig. S2D).
Fungal Growth Inhibition by AHAS-Inhibiting Herbicides. The five
classes of commercial herbicide that target AHAS were assessed
for their ability to prevent the growth of five Candida species (C.
albicans, Candida parapsilosis, C. glabrata, Candida tropicalis, and
C. krusei), C. neoformans, and S. cerevisiae in culture (SI Ap-
pendix, Table S2). CE was found to display broad-spectrum an-
tifungal activity, being highly effective in preventing the growth
of C. albicans, C. parapsilosis, C. glabrata, and S. cerevisiae with MIC
values as low as 0.03 μg/mL (72.32 nM), 0.003 μg/mL (7.23 nM),
0.005 μg/mL (12.05 nM), and 0.008 μg/mL (19.29 nM), respectively
(Table 2), while other herbicides, including MT, are also effective at
preventing growth, but not with the same level of broad-spectrum
activity (SI Appendix, Table S2). Independent of the strain tested,
some herbicides reduced growth for 24 h, whereas CE, among
others, maintained potency for up to 72 h (Fig. 5A and SI Appendix,
Table S2). CE has a minimum fungicidal concentration (MFC) for
C. albicans that is four times MIC, and thus is considered fungicidal
rather than fungistatic (Table 2).
Antifungal Activity of CE Is Enhanced by Itraconazole. To test if
the current first-line antifungal compounds, fluconazole, itraco-
nazole, or amphotericin B, can influence the activity of CE in
reducing the growth of C. albicans, a grid experiment was per-
formed. This showed that CE in combination with itraconazole
had a synergistic effect, resulting in a fractional inhibitory con-
centration (FIC) value of 0.63 (Fig. 5B, Top). In addition, an
additive interaction was observed when CE and amphotericin B
were combined (FIC = 1). In contrast, the combination of CE
with fluconazole shows an antagonistic interaction (FIC = 1.5). It
is worth noting that fluconazole (a fungistatic agent) is an an-
tagonist of other antifungal drugs, for example amphotericin B (a
fungicidal) (28), an interaction usually observed when the drugs
have different mechanisms of action.
A method that plants adopt to detoxify AHAS-inhibiting
herbicides is to use P450 enzymes. This is achieved by adding
or removing functional groups, thereby preventing binding to the
enzyme (29, 30). Azoles are potent inhibitors of the fungal cy-
tochrome P450 lanosterol 14-α-demethylase (CYP51A1). They
also have activity toward human P450 enzymes (CYP3A4 and
CYP2C9), increasing the serum concentration of several drugs
(31). Therefore, we hypothesize itraconazole may inhibit CE
degradation via P450s, thus maintaining the concentration of the
compound in the cell for a longer time period. This implies
existing fungal P450s can play a role in reducing the antifungal
activity of those herbicides that are susceptible to modification.
To answer this question, a synergy grid experiment was per-
formed using PS, a TP that has a low MIC value for C. albicans
growth of 6.41 μg/mL after 48 h, but which loses activity after
72 h (MIC = 185.5 μg/mL) (Fig. 5A), in combination with flu-
conazole, itraconazole, or amphotericin B. The results show that
only itraconazole enhances the longevity of antifungal activity of
PS (synergistic effect, FIC = 0.31) (Fig. 5B, Bottom), resulting in
a >15-fold reduction in MIC value for PS after 72 h. However,
adding fresh PS alone after 24, 48, and 72 h to concentrations
equal to those used in the microdilution tests or additive self-
drug combination of PS did not produce an improvement in the
MIC values. These data suggest that itraconazole could be
coadministered to minimize the effect of herbicide metabolism.
Effect of BCAA Supplementation on the Antifungal Activity of CE.
Next, we investigated whether BCAA supplementation affects
the efficacy of CE in reducing the growth of five Candida species
and C. neoformans in culture media. Compared with the control
[yeast nitrogen base (YNB) broth supplemented with 10 mM
proline as nitrogen source], the addition of BCAAs (10 mM;
>15-fold the concentration found in human blood) as sole ni-
trogen source produces a shift in the MICs of CE for all five
Candida strains. C. neoformans is unable to grow under these
conditions (15) (Fig. 5C). The effect of BCAAs on C. albicans
growth in the presence of CE is significantly lower (2.3-fold in-
crease of MIC) compared with that of the other Candida strains
(>20-fold increase of MIC). The inclusion of proline along with
BCAAs partially restores the antifungal activity of CE against
C. albicans, C. parapsilosis, and C. tropicalis (Fig. 5C). In this
situation, C. neoformans growth was viable (15) with a twofold
increase in the MIC of CE. Given that serum albumin could be a
potential source of BCAAs during fungal infections, we next
investigated the effect of BSA (4 g/L) on the performance of CE.
These results showed that only C. glabrata and C. parapsilosis can
partially bypass AHAS inhibition through scavenging BCAAs from
BSA (8.3- and 2.9-fold increase of MIC, respectively). Remarkably,
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Fig. 2. CaAHAS structure. (A) Overall fold of the uninhibited CaAHAS tet-
ramer in cartoon representation. The cofactors ThDP (white) and FAD (yel-
low) are drawn as ball and sticks models, and the magnesium ion is depicted
as a dark cyan sphere. (B) Cartoon representation of a single subunit of
CaAHAS in complex with CE. The three domains: α (76–272), β (273–454), and
γ (468–639) are colored in different shades of green. The two elements of
the capping region, the “mobile loop” (Q576-Y591) and “C-terminal arm”
(P646-Y683), which are key for trapping the herbicide in its binding pocket,
are colored magenta and blue, respectively. The carbon atoms in CE are
colored cyan. A green broken line represents the N267–A276 region, which is
disordered in all structures. (C) 2Fo − Fc electron density maps (contoured
at ≥2.0 σ) for ThDP, ThAthDP, ThThDP, ThThDP/ThAthDP, and ThFAthDP/
ThAthDP in the uninhibited enzyme (2.9-Å resolution), the IE (1.8-Å resolu-
tion), PC (2.4-Å resolution), MT (2.1-Å resolution), and CE (2.1-Å resolution)
complexes, respectively. (D) Connolly surface showing CE (cyan) inserted into
the substrate access channel thereby blocking the active site, where ThDP
(white) is located (enclosed in B with broken lines). Nitrogen, blue; oxygen,
red; sulfur, yellow; potassium, magenta; and chlorine, pink.
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the MIC of CE against C. neoformans was reduced a further 5.5-
fold compared with the control under this assay condition (Fig. 5C).
To identify the requirements of these fungal pathogens to
circumvent AHAS inhibition in the presence of BCAAs, we next
assessed the growth of C. albicans in YNB broth with leucine,
valine, isoleucine, proline, and/or ammonium sulfate as the only
nitrogen source or in combinations, and in the presence of dif-
ferent concentrations of CE (Fig. 5D). These experiments
showed that the addition of 10 mM valine, leucine, or isoleucine
as the sole nitrogen source does not affect the efficacy of CE in
preventing C. albicans growth. Indeed, the MICs of CE de-
termined under these conditions are lower compared with the
MIC determined using YNB media supplemented with 10 mM
ammonium sulfate or proline. However, the combination of va-
line and isoleucine suppresses significantly the antifungal activity
of CE (MIC = 5.6 μg/mL), while this effect is nullified by addi-
tion of leucine, proline, or ammonium sulfate (Fig. 5D). Amino
acid transport is highly regulated by the nitrogen catabolite re-
pression or the Ssy1p-Ptr3p-Ssy5p systems, the intracellular and
extracellular amino acid ratio, and the presence of nitrogenated
molecules in the environment (32, 33). Ammonium diminishes
BCAA transport via Gap1 (Gap2 in C. albicans) and Bap2 re-
pression (34, 35), a mechanism which explains why ammonium
sulfate restores the antifungal activity of CE in the presence of
BCAAs. In agreement with this result, 100 μg/mL eugenol, an in-
hibitor of BCAA permeases (36), synergizes with CE (FIC 0.38; 48-
h MICCE = 0.125 μg/mL) against C. albicans when BCAAs are
present in the growth media (SI Appendix, Fig. S10). However, while
it has been shown that proline derepresses BCAA transport (34),
here we observed that it also diminishes the ability of C. albicans to
bypass AHAS inhibition by taking up BCAAs from the media. In
addition, we observed when leucine, valine, and isoleucine are
added in combination in the media, growth is reduced (Fig. 5E).
This could be due to reciprocal competition as the three BCAAs try
to use the same method of transport into the cell (37) (Fig. 5E). It
has been shown that absence of valine is highly detrimental for C.
albicans AHAS (ilv2Δ) mutant growth (14). Here, we show valine
increases the growth of C. albicans and that both leucine and iso-
leucine compete with valine, as seen by a 15% reduction in fungal
growth when these are in combination (Leu–Val or Ile–Val). Iso-
leucine also inhibits growth in presence of leucine and the combi-
nation of the three BCAAs yields 35% less growth compared with
that observed when valine is the nitrogen source (Fig. 5E). These
results suggest that, even though C. albicans is able to scavenge
BCAAs from the environment and, to some extent, bypass AHAS
inhibition by herbicide to support growth, the intricate interactions
between substrates and amino acids limit the absorption of BCAAs
and therefore add further support for the concept of using AHAS-
inhibiting herbicides to treat human fungal infections.
Antifungal Activity of CE in Vivo. We next assessed if CE could be
an effective antifungal agent in mice. First, we performed a
toxicity study where CE was injected i.p. twice per day and
showed that by this procedure over a 7-d period doses as high as
500 mg·kg−1·d−1 were tolerated by the mice, with no adverse
effects. To assess the efficacy of CE we infected groups of
10 mice via tail vein with C. albicans (strain SC5314; 24-h MIC of
CE = 0.05 μg/mL) and tested their ability to survive given dif-
ferent doses of CE (100 and 500 mg·kg−1·d−1) delivered in two IP
injections, each including half of the daily dose of CE. PBS and
fluconazole (200 mg/kg/d) were included as negative and positive
controls and delivered in the same way as CE. Weight loss is a
gold-standard symptom indicative of disseminated fungal in-
fection (38) and we used this reference to assess the severity of
the infection. With this premise, only one mouse in the PBS
group did not show signs consistent with the disease (Fig. 6A)
and therefore was not considered in the final statistical analysis,
while all mice receiving CE or fluconazole showed signs consis-
tent with the disease (i.e., weight loss) (Fig. 6A). Compared with
the control group receiving PBS, the results show that admin-
istration of CE prolongs the life of the infected mice in a
concentration-dependent manner (Fig. 6A). Organ fungal bur-
den analysis of kidneys, spleen, liver, lungs, and brain showed
that all mice that survived until the end of the experiment, except
one individual receiving fluconazole, had cleared the infection
Fig. 3. Proposed mechanism for AHAS modification of ThDP. Our kinetic, structural, and MS data suggest that, upon herbicide binding, ThDP is primarily
altered into two analogs: ThThDP or ThAthDP. Turnover conditions and molecular oxygen [which binds AHAS nearby ThDP (59)] are required for this to occur
(23, 24), implying that the presence of the hydroxyethyl (He) ThDP intermediate in the active site is required for either herbicide binding and/or the gen-
eration of peracetate, a product of the oxygenase activity of AHAS (60). From these results, the following mechanism has been developed. In pathway a, free
peracetate or molecular oxygen (61, 62) (both trapped in the active site by the herbicide) (24) react with the C2 carbene of ThDP, producing ThThDP. The
thiazolone ring is then hydrolyzed by hydroxide and ring-opened, leading to intermediate thiamine ethenethiolcarbamate diphosphate (ThEthCDP), which
undergoes decarboxylation of the carbamic acid group to give ThAthDP (63). Alternatively, in pathway b, ThAthDP is produced by a parallel mechanism that
involves direct nucleophilic ring opening of the thiazolium ring of ThDP, producing formamidoethenethiol diphosphate (ThFAthDP) (62, 64). Hydroxide then
induces cleavage of the N–CHO bond to give ThAthDP (65). The ThDP related molecules depicted in blue have been observed in the crystal structures of AHAS
in complex with the herbicide, except for intact ThDP, which is observed in the crystal structure of uninhibited CaAHAS.
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(Fig. 6B). In addition, CE significantly decreased fungal load in
the spleen, liver, lungs, and brain compared with those mice
without receiving antifungal treatment, suggesting that the her-
bicide is able to reach its target via an adequate distribution of
the herbicide in these organs. Importantly, CE is effective in
clearing infection from the lungs and liver, even at low concen-
trations (Fig. 6B). Previous studies have shown that the SUs are
readily absorbed following oral administration (17, 39); there-
fore, here we additionally show that i.p. injection is also a viable
route for drug administration. The SUs, including CE, and most
AHAS-inhibiting herbicides show a pH-dependent solubility in
aqueous solutions, with these compounds becoming insoluble at
low pH. We therefore hypothesize the weaker effect of CE in
reducing the fungal burden in the kidneys could be due to pre-
cipitation of the compound in urine (40).
Discussion
Since the discovery that AHAS is essential for virulence and
survival of C. albicans and C. neoformans cells in vitro and in vivo
(14, 15), this enzyme has been proposed as a potential target for
developing antifungal compounds. Preliminary studies have
shown that inhibitors targeting AHAS have antifungal activity
against C. albicans, C. neoformans, and A. fumigatus in culture
(18, 19). Here, we have performed a comprehensive study to
identify drug lead candidates with potent antifungal activity
within the five families of AHAS-inhibiting herbicides. Our ki-
netic assays concluded that CE and several other AHAS inhib-
itors of the SU and TP families show potent inhibition of
CaAHAS and CnAHAS that also correlates with strong anti-
fungal activity. The ability of the herbicides to induce accumu-
lative inhibition via ThDP alteration and FAD oxidation (23, 24)
is an important determinant in how effective these compounds
are in biological assays, so should be a key factor in consideration
of the design of AHAS inhibitors to act as antifungal drugs.
Importantly, CE stands out over all commercial herbicides tested
in this study because it possesses a broad spectrum of antifungal
activity against five different Candida species and C. neoformans
and is fungicidal against C. albicans in vitro. Our cell-based
studies suggest several fungal pathogens have the ability to de-
toxify some AHAS-inhibiting herbicides via P450s. It is worth noting
that CE and the other commercial AHAS inhibitors assayed here
were developed to possess crop vs. weed selectivity via herbicide
detoxification. O-dealkylation of the methoxy substituents at the
heterocyclic ring via P450s is an example of how plants detoxify
AHAS inhibitors by affecting their performance (16), suggesting a
similar mechanism could occur in fungi. CE has a chlorine atom
attached to the heterocyclic ring, a unique feature among the com-
mercial herbicides tested (SI Appendix, Fig. S1). Accordingly, CE is
effective in reducing the growth of a number of fungal pathogens over
a period of 72 h, indicative that this herbicide is less affected by de-
toxification. In this context, we have shown itraconazole enhances the
antifungal activity of AHAS inhibitors, suggesting there is potential to
exploit/develop specific fungal P450 inhibitors to further maximize
the performance of CE and other herbicides that target AHAS.
The broad-spectrum antifungal activity of CE is a result of the
high conservation of the AHAS herbicide-binding site across
fungi (SI Appendix, Fig. S2). Of those residues forming direct
contacts with the herbicides, only four have been changed dur-
ing evolution and are located at the entrance of the binding
cavity (SI Appendix, Fig. S2B). The A653G substitution observed
in ScAHAS and C. parapsilosis AHAS has little effect, since
ScAHAS (41) and S. cerevisiae and C. parapsilosis cells are highly
susceptible to AHAS inhibitors. However, C. neoformans is re-
sistant to the SU herbicide, SM (15). Modeling suggests this is
in part due to the P188A and A191L substitutions in CnAHAS
(SI Appendix, Fig. S2 C and D). Based on these findings it was
advocated AHAS inhibitors might not be suitable for treating
infections caused by this pathogen. While we have confirmed
CnAHAS exhibits a natural insensitivity to several AHAS-inhibiting
herbicides of the SU (including SM, BSM, and ES), SCT, and IMI
families, we also observed that CE (a SU) and MT and CSM (TPs)
inhibit this enzyme at the low-nanomolar level. Models of the
P188A and A191L substitutions in CaAHAS and our kinetic data
show that CE is effective in inhibitingCnAHAS because it possesses
a longer ethyl ester substituent at the aromatic ring and this con-
tributes to anchoring the herbicide in its binding cavity even in
presence of these two unfavorable substitutions (SI Appendix, Fig.
S2C). The TPs, including MT and CSM, are potent inhibitors of
CnAHAS because this family of herbicides form fewer contacts with
P188, their linker has more flexibility (SI Appendix, Fig. S2D), and
these locate the aromatic ring deeper in the herbicide-binding site
compared with the SUs (SI Appendix, Fig. S9). For future drug
design efforts, a focus should be placed on developing inhibitors
that bind only to the highly conserved residues in the AHAS binding
site. This should reduce the propensity for resistance to develop.
Previous studies point out the possibility that fungal pathogens
might scavenge BCAA from the hosts’ serum and bypass AHAS
inhibition by herbicides (15, 19). Here, we show the antifungal
activity of CE against C. albicans, C. parapsilosis, C. tropicalis,
and C. neoformans is not affected by BCAA supplementation,
which is a product of the complex regulation of BCAA absorp-
tion by BCAAs themselves and by other molecules that could
serve as nitrogen source (e.g., ammonium ions or proline).
A B C
Fig. 4. SU, TP, and SCT binding sites in CaAHAS. (A)
CE, (B) MT, and (C) PC. The herbicides and key resi-
dues for herbicide binding are depicted in stick
models, whereas the polypeptide is shown in ribbon
display with each subunit colored differently. Hy-
drogen bonds formed between the herbicides and
the polypeptide are presented as dashed lines.
Table 2. MIC and MFC of CE for fungal pathogen growth in cell
culture
MIC50 MIC*
MFC/MICFungal species μg/mL nM μg/mL nM
Ca 0.030 72.32 0.070 168.7 4
Cg 0.005 12.05 0.010 24.1 >8
Cp 0.003 7.23 0.004 9.6 8
Ct 0.550 1.33 × 103 1.450 3.5 × 103 8
Ck 0.430 1.04 × 103 1.960 4.7 × 103 >8
Cn 2.750 6.63 × 103 7.980 19.2 × 103 >8
Sc† 0.008 19.29 0.02 48.2 2–4
MIC50 and MIC values determined after 24-h culture.
*The MIC values for fluconazole were 0.31 μg/mL (C. albicans, Ca), >100 μg/mL
(C. glabrata, Cg), 4.66 μg/mL (C. parapsilosis, Cp), 6.22 μg/mL (C. tropicalis, Ct),
25.81 μg/mL (C. krusei, Ck), 15.34 μg/mL (C. neoformans, Cn), and 17.03 μg/mL
(S. cerevisiae, Sc).
†MIC50 and MIC values determined after 48-h culture.
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Further supporting our observation, there is evidence during
protein synthesis inhibition, which is the latter effect of blocking
BCAA biosynthesis by herbicide, endogenous amino acids ac-
cumulate inhibiting amino acid uptake below detection limits
(42). Conclusively, CE is effective in reducing fungal burden in
the spleen, liver, lungs, and brain of mice systemically infected
with C. albicans, confirming that the hosts’ BCAAs absorbed by
this pathogen during infection cannot completely bypass AHAS
inhibition by CE. Therefore, we identify the SU herbicides as
having great potential to be developed as a novel class of anti-
fungal drugs to treat human fungal pathogenic infections.
Conclusions
Here, AHAS-inhibiting commercial herbicides, developed to
efficiently kill weeds over crops, were assessed as antifungal
agents. This is possible by taking advantage of the fact that the
sequences of AHAS are highly conserved across both kingdoms
and the activity of this enzyme is essential for the survival of plants
and microorganisms. The absence of this enzyme in mammals and
the low toxicity of AHAS inhibitors in humans (17) make them an
appealing class of compound to be optimized into therapeutic
agents to treat infections due to microbial pathogens.
The kinetics of inhibition of CaAHAS and CnAHAS by rep-
resentatives of the five families of commercial herbicides were
determined and these served to identify several potent accu-
mulative inhibitors of these enzymes. CaAHAS inhibition by
these herbicides is different from that observed when they bind
to ScAHAS. In ScAHAS much of the polypeptide has to fold
around these compounds to optimize binding. However, in
CaAHAS no major conformational changes occur. This is a key
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Fig. 5. Fungal growth inhibition by herbicide. (A) Percentage of C. albicans cell growth vs. log10 [CE] or [PS] after 24, 48, and 72 h. The solid lines represent the
best fit to the data using the modified Gompertz function (57). (B) Isobolograms showing the interactions between CE (Top) or PS (Bottom) and three front-line
antifungal drugs against C. albicans growth. The FICCE are defined as the MIC of CE in combination with an antifungal drug (itraconazole, fluconazole, or
amphotericin B) divided by the MIC of CE alone. A straight line represents an additive interaction (CE–amphotericin B combination), a concave curve indicates
synergy (CE–itraconazole combination), and a convex curve shows antagonism (CE–fluconazole interaction). The FIC values for PS and each antifungal drug were
determined in the sameway. AmB, amphotericin B; Flu, fluconazole; Itr, itraconazole. (C) Fungal growth inhibition by CE in presence of different nitrogen sources:
(i) 10 mMproline (blue lines); (ii) 2.5 mMproline, 2.5 mM leucine, 2.5 mM valine, and 2.5 mM isoleucine (red lines); (iii) 3.3 mM leucine, 3.3 mM valine, and 3.3 mM
isoleucine (black lines); and (iv) 4 g/L BSA (magenta lines). The MIC values were determined at 48-h incubation using the modified Gompertz function. Note that
the substitution of ammonium sulfate for proline, as the nitrogen source, does not produce a significant change in the MIC values reported in SI Appendix, Table
S2. (D) Inhibition of C. albicans growth by CE in presence different combinations of BCAAs. YNBmedia was supplemented with 5 mM valine, 5 mM leucine, and/or
5 mM isoleucine in the presence or absence of 10 mM ammonium sulfate or 10 mM proline. (E) C. albicans growth in the presence of different combinations of
BCAAs (5 mM each) and in the absence of herbicide. Error bars represent the SD of the mean (SEM) (n = 3).
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finding because it allows the rational structure-based design of
inhibitors based on the native structure of CaAHAS. Previously,
we have demonstrated AHAS inhibitors are able to take full
advantage of the high reactivity of ThDP and to induce reactions
that lead to the ultimate inactivation of this cofactor (23, 24).
Here, the crystallographic data and MS allowed us to describe
the mechanism by which the herbicides convert ThDP into
ThThDP and ThAthDP.
Our cell-based assays provide unique insights into the patho-
gens’ response to the potent antifungal activity of several com-
mercial herbicides that target AHAS and the potential use of
P450 inhibitors to further enhance antifungal activity and to di-
minish the prospects of the development of resistance. More
importantly, CE possesses antifungal activity in mice infected
with C. albicans, which illustrates CE is a drug lead suitable for
further development and that AHAS inhibitors have great
promise to treat human pathogenic fungal infections.
Methods
Cloning of CnAHAS and CaAHAS. The ORF for the catalytic subunit of the
CnAHAS gene was amplified from C. neoformans cDNA. The first 101 aa
corresponding to the mitochondrial transit peptide were deleted using the
forward primer 5′-AAAGGATCCATGCCCACTAATATGCC-3′, which contains a
BamHI site at the N terminus to facilitate its cloning into pET30a(+) vector.
The reverse primer was 5′-TCTGCGGCCGCTTACTCAGAGCCGTTCCG-3′ and
contains a NotI restriction site after the stop codon. This construct therefore
encodes the first 50 residues of the vector, including a hexahistidine tag,
followed by the CnAHAS polypeptide from M102 to E718. Cloning of the
CaAHAS catalytic subunit into pET30a(+) vector was reported previously
(18). The CaAHAS and CnAHAS constructs were then transformed into
Escherichia coli strain Rosetta BL21(DE3) and BL21(DE3)pLysS, respectively,
for protein expression.
Protein Expression and Purification. Expression and purification of the catalytic
subunits of CaAHAS and CnAHAS was carried out as reported previously for
AtAHAS (23). The enzymes were stored in aliquots of 30 μL at −70 °C. Protein
concentration was measured using the Direct Detect system (Merck Millipore).
AHAS Assay. For all assays, unless specifically stated, the standard reaction
buffer contained 200 mM potassium phosphate (pH 7.2), 100 mM sodium
pyruvate, 10 mM MgCl2, 1 mM ThDP, and 10 μM FAD and assays were con-
ducted at 30 °C. Measurement of Ki values was carried out in triplicate using a
colorimetric method (43) and partial anaerobic conditions as described pre-
viously (23). These values were then calculated by nonlinear regression using
Eq. 1 [weak to medium binding (44)] or Eq. 2 [tight binding (18)]:
vi = vo=ð1+ ½I=KiÞ [1]
vi
2½Eo + vovi
½Io − ½Eo +Ki− vo2Ki = 0. [2]
For accumulative inhibition assays, 1 μM enzyme was assayed in triplicates
using a continuous method (45). The reaction buffer for these assays con-
tained 50 mM pyruvate. The inhibitors were added 15 min after the enzyme
so that inhibition could be measured when maximum activity of the enzyme
was attained. The reaction was then monitored for a further 35 min. The
data were fitted using Eq. 3 (20) for the calculation of kiapp and k3 involved
in accumulative inhibition:
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Fig. 6. Survival of BALB/c mice infected i.v. with C. albicans. (A) Percentage of mouse weight postinfection. Mice (n = 10 per group) received PBS, fluconazole
(200 mg·kg−1·d−1), CE (100 mg·kg−1·d−1), or CE (500 mg·kg−1·d−1) via i.p. injection over a 7-d period after i.v. infection with C. albicans (Methods). The weight
of the mice was recorded every day for the duration of the experiment (40 d), and mice were killed by CO2 asphyxiation when they showed ≥20% weight loss
or signs consistent with disseminated candidiasis. Each mouse showed weight loss for at least four consecutive days postinfection. Black lines represent each
individual within groups, red lines the mean of each group, and a blue line represents an outlier in the PBS group that did not show signs of infection (i.e.,
weight loss). (B) Organ burden analysis calculated in colony forming units (CFU) per gram of tissue. One-way ANOVA test was performed to determine
statistical significance (kidney: F = 17.82, P < 0.0001; spleen: F = 18.26, P < 0.0001; liver: F = 14.87, P < 0.0001; lung: F = 8.93, P = 0.0002; and brain: F = 17.7, P <
0.0001; degrees of freedom = 3 for treatments and 35 for residuals), followed by Tukey test (α = 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001).
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For BS, CS, DS, FS, FT, IM, PC, PS, PTB, PYS, SM, and TCM, their relatively high Ki
values were taken into account for the estimation of the value F (free en-
zyme/enzyme.inhibitor complex ratio). The effective concentration of en-
zyme.inhibitor was calculated using Eq. 4 (inhibition constant formula), the
known initial concentrations of enzyme and inhibitor, and the Ki value of
Table 1:
Ki = ð½E. ½IÞ=½EI. [4]
Protein Crystallization and Structure Determination. Crystallization trials were
performed using the hanging-drop vapor-diffusion method as described
previously (23). The protein solution included freshly thawed protein
(30 mg/mL), 5 mM MgCl2, 1 mM ThDP, 1 mM FAD, 5 mM DTT, 3 mM sodium
pyruvate, and, when appropriate, 1 mM herbicide. The hanging drops con-
sisted of protein and well solution in a 2:1 ratio. For uninhibited CaAHAS and
the CaAHAS–MT complex, the well solution contained 1 M Na/K tartrate,
0.1 M 2-(N-cyclohexylamino)ethanesulfonic acid, and 0.2 M Na2SO4. The pH of
the solution ranged from 9.4 to 9.8. Crystals for the remaining CaAHAS-herbicide
complexes were obtained in similar way, with the only difference being the well
solution contained (NH4)2SO4 instead of Na2SO4. The crystallization experiments
were kept at 290 K and protected from light until the crystals reached their
maximum size. For cryocooling the crystals were transferred to a drop containing
well solution, 35% vol/vol ethylene glycol, cofactors, and inhibitor (when ap-
propriate), mounted in cryoloops and frozen in liquid nitrogen.
The datasets of the uninhibited CaAHAS and the CaAHAS–herbicide
complexes were collected at the Australian Synchrotron. The datasets were
indexed, integrated, and scaled using XDS (46) and Aimless (47). The crystal
structure of uninhibited CaAHAS was solved by molecular replacement with
PHASER (48) using ScAHAS in complex with chlorsulfuron (Protein Data Bank
ID code 1T9B) as the starting model. Model building was carried out using
Coot 0.8.1 (49) and refinement was with PHENIX 1.9-1692 (50). The crystal
structures of CaAHAS in complex with herbicides were then solved by the
same method using the uninhibited CaAHAS as the starting model. Figures
were generated with CCP4mg (51).
Protein Sequence Alignment Protein–Ligand Interaction Analysis. The amino
acid sequences for the AHAS catalytic subunits of C. albicans (XP_721571.1),
C. glabrata (XP_448375.1), C. parapsilosis (CCE44821.1), C. tropicalis
(XP_002548114.1), C. krusei (KGK39551.1), C. neoformans (AAR29084.1), A.
fumigatus (EAL92550.1), and S. cerevisiae (NP_013826.1) were obtained from
GenBank and sequence alignment was performed with Clustal Omega (52).
Interactions with each herbicide in CaAHAS were analyzed using Arpeggio (53).
CnAHAS Herbicide-Binding Site Model. The P188A and A191L substitutions
present in CnAHAS were modeled in the 3D coordinates of uninhibited
CaAHAS and the CaAHAS-CE/MT complexes using Coot 0.8.1 (49) and
structure optimization was carried out with Yasara (54).
MS. Samples for MS analysis of ThDP were prepared as described previously
(23). One microliter of each sample was then injected onto an Agilent
InfinityLab Poroshell 120 EC-C18 column (2.1 × 50 mm). Liquid chromatog-
raphy gradient was 0–98% B over 7 min, run at 100 μL/min, with the column
oven set to 45 °C. Eluted samples were sprayed using a heated electrospray
ionization source and analyzed on an Orbitrap Elite mass spectrometer.
Source parameters included capillary temperature = 320 °C, source heater
temperature = 200 °C, sheath gas = 25 L/min, auxiliary gas = 8 L/min, source
voltage = 4.5 kV, and s-lens = 60%. Samples were analyzed with the Orbi-
trap analyzer set to 30,000 resolution.
Cell-Based Studies. Antifungal susceptibility testing was performed using the
broth microdilution method according to a standard protocol (55). All ex-
periments were performed in 96-well plates using YNB broth without amino
acids and ammonium sulfate (BD Difco) supplemented with 2% glucose,
100 mM (NH4)2SO4, and 50 mM Hepes. The pH of the media was adjusted to
7.2 to ensure inhibitor solubility and stability (56). The herbicides were dis-
solved in DMSO and then serially diluted in 96-well plates using YNB. The
herbicide solutions were used fresh and kept at −20 °C for no more than
1 wk. The latter was particularly important to guarantee accurate MIC
measurements, since some of the herbicide tested had degraded when
stored in DMSO for prolonged periods (>1 wk). The well-established anti-
fungal drugs fluconazole and itraconazole were used as controls. All studies
were conducted using C. albicans ATCC 90028, C. glabrata ATCC 90030, C.
parapsilosis ATCC 22019, C. tropicalis ATCC 750, C. krusei ATCC 6258, C.
neoformans ATCC 90113, and S. cerevisiae Sigma 1278b. Growth was
determined by measuring the OD530 every 24 h using a Molecular Devices
Spectramax 250 microplate reader (Marshall Scientific). The MIC50 and MIC
values were determined using the modified Gompertz function (57). All
experiments were conducted in triplicate, with each performed on a dif-
ferent day. The MFC was determined as described previously (58).
The FIC index of CE and PS in combination with fluconazole, itraconazole,
or amphotericin B against C. albicans growth was determined using a syn-
ergy grid experiment in a microdilution format as described above. The FIC
values for CE (FICCE) were defined as the MIC of CE in combination with an
antifungal drug (itraconazole, fluconazole, or amphotericin B) divided by
the MIC of CE alone. The FIC values for PS and each antifungal drug were
determined in the same way. The FIC index for each drug combination was
calculated as FICherbicide + FICantifungal drug. Synergism is defined as FIC index
values <1, antagonism by FIC index values >1, and additivity by FIC index
values = 1. All experiments were conducted in triplicate.
The effect of BCCAs and BSA on the antifungal activity of CEwas measured
in triplicate using broth microdilution in a 96-well plate format as described
above, with the only difference being (NH4)2SO4 was replaced by (i) 10 mM
proline; (ii) 2.5 mM proline in addition to different combinations of BCAAs:
2.5 mM leucine, 2.5 mM valine, and/or 2.5 mM isoleucine; (iii) 3.3 mM of
each BCAA as sole nitrogen source; or (iv) 4 g/L BSA as sole nitrogen source.
Inhibition of C. albicans growth by CE in the presence different combinations
of BCAAs was measured using YNB broth supplemented with 5 mM valine,
5 mM leucine, and/or 5 mM isoleucine in the presence or absence of 10 mM
ammonium sulfate or 10 mM proline.
Mouse Studies. A mouse model study of disseminated C. albicans infection
was conducted following the requirements of animal welfare in accor-
dance with the Australian Code for the Care and Use of Animals for Sci-
entific Purposes by the National Health and Medical Research Council, and
after approval by the Molecular Biosciences Animal Ethics Committee (AEC)
of The University of Queensland (AEC approval no. SCMB/175/17).
For toxicity assays of CE in mice, 25 6-wk-old BALB/c mice received 0.1-mL
PBS injections via the tail vein using a 1-mL tuberculine syringe and a 27-
gauge, 0.5-inch needle. Subsequently, five mice received one of two different
doses of CE (100 or 500 mg·kg−1·d−1) delivered by two i.p. injections (morning
and evening), each containing half of the daily dose dissolved in 100 μL PBS
(adjusted to pH 8). Fluconazole (200 mg/kg/d) and PBS alone were used as
controls and delivered in the same way as CE. All injections were applied
using a 1-mL tuberculine syringe and a 27-gauge, 0.5-inch needle. Weight
and aspect of the mice were examined on day 1 and every day after for 2 wk,
at which point all mice were killed via CO2 inhalation. Kidneys, spleen, liver,
lungs, and brain were collected to record organ weight and aspect. Mice
were provided with food and water for ad libitum intake and with card-
board as environmental enrichment.
For murine infection assays, 40 6-wk-old female BALB/c mice were infected
by tail-vein injection of 0.1 mL PBS containing 106 viable cells (38) using a
1-mL tuberculine syringe and a 27-gauge, 0.5-inch needle. Mice were sepa-
rated in groups of 10 and treated during a 7-d period, beginning the same
day of infection with two different doses of CE (100 and 500 mg·kg−1·d−1),
fluconazole (200 mg·kg−1·d−1), or PBS delivered in 100-μL i.p. injections twice
per day (morning and evening) as described above. A maximum of five mice
were housed per individually ventilated cage and provided with food and
water for ad libitum intake and cardboard. The weight and aspect of the
mice were monitored daily during the duration of the experiment (40 d).
Mice were killed via CO2 asphyxiation once they declined to ≥80% of
preinfection body weight or when symptoms consistent with infection
were obvious. The date of death was recorded as the following day. Kid-
neys, spleen, liver, lungs, and brain were collected and homogenized in
1 mL PBS using a TissueLyser II (Qiagen) and plated on YPD agar containing
25 μg/mL chloramphenicol, 50 μg/mL kanamycin, and 100 μg/mL ampicillin
in 1:10 serial dilutions. The colony-forming units per gram of tissue were
determined after 24 h incubation at 30 °C. One-way ANOVA was per-
formed to determine statistical significance within organ fungal burden
datasets, followed by the Tukey test.
The inoculum for mice infection was prepared from fresh cultures of C.
albicans strain SC5314 plated on YPD agar from a glycerol stock and in-
cubated at 30 °C for 48 h. A single colony was transferred to 10 mL YPD
broth and further incubated at 30 °C with shaking (150 rpm) for 20 h. Cells
were harvested by centrifugation (800 × g) for 1 min at room temperature
and washed twice with sterile PBS and the cell density was adjusted to 1 ×
107 cells per mL using a hemocytometer. The cell suspension was kept on ice
and used immediately. Cell concentration was confirmed by plating
1:10 serial dilutions on YPD agar and incubated for 24–48 h at 30 °C.
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